Notable Reporting: Will Genocea Biosciences Inc Go Down Anytime Soon?

Notable Reporting: Will Genocea Biosciences Inc Go Down Anytime Soon?

The stock of Genocea Biosciences Inc (NASDAQ:GNCA) is a huge mover today! The stock increased 3.61% or $0.15 on November 23, hitting $4.31. About 80,423 shares traded hands. Genocea Biosciences Inc (NASDAQ:GNCA) has declined 21.64% since April 22, 2016 and is downtrending. It has underperformed by 27.05% the S&P500.
The move comes after 8 months positive chart setup for the $119.45M company. It was reported on Nov, 24 by We have $4.70 PT which if reached, will make NASDAQ:GNCA worth $10.75M more.

Analysts await Genocea Biosciences Inc (NASDAQ:GNCA) to report earnings on February, 9. They expect $-0.47 earnings per share, down 27.03% or $0.10 from last year’s $-0.37 per share. After $-0.45 actual earnings per share reported by Genocea Biosciences Inc for the previous quarter, Wall Street now forecasts 4.44% negative EPS growth.

Genocea Biosciences Inc (NASDAQ:GNCA) Ratings Coverage

Out of 4 analysts covering Genocea Biosciences (NASDAQ:GNCA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $22 is the highest target while $12 is the lowest. The $15.60 average target is 261.95% above today’s ($4.31) stock price. Genocea Biosciences has been the topic of 7 analyst reports since August 6, 2015 according to StockzIntelligence Inc. FBR Capital maintained Genocea Biosciences Inc (NASDAQ:GNCA) rating on Monday, October 19. FBR Capital has “Outperform” rating and $17 price target. Needham maintained Genocea Biosciences Inc (NASDAQ:GNCA) rating on Thursday, September 29. Needham has “Buy” rating and $15 price target. The company was maintained on Thursday, September 29 by PiperJaffray. The rating was maintained by Piper Jaffray on Thursday, August 6 with “Overweight”. The firm has “Buy” rating by Needham given on Tuesday, August 11. UBS initiated the shares of GNCA in a report on Thursday, December 17 with “Buy” rating. Needham maintained Genocea Biosciences Inc (NASDAQ:GNCA) rating on Tuesday, October 20. Needham has “Buy” rating and $15 price target.

According to Zacks Investment Research, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts.”

More important recent Genocea Biosciences Inc (NASDAQ:GNCA) news were published by: which released: “/quotes/zigman/3870025/realtime” on February 05, 2014, also published article titled: “Why It’s Been a Wild Few Days for Genocea Biosciences Inc.”, published: “Why Genocea Biosciences Inc Stock Dropped Today” on July 30, 2015. More interesting news about Genocea Biosciences Inc (NASDAQ:GNCA) was released by: and their article: “Genocea Biosciences Rises on Positive Herpes Trial Results” with publication date: October 29, 2016.

GNCA Company Profile

Genocea Biosciences, Inc., incorporated on August 16, 2006, is a biopharmaceutical company. The Firm discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses, in contrast to approved vaccines and immunotherapies, which are designed to act primarily through B cell (or antibody) immune responses. The Company’s ATLAS discovery platform is designed to overcome the challenges associated with developing vaccines that stimulate T cell immunity. The Company’s ATLAS is a throughput system for T cell vaccine and immunotherapy discovery. The Firm operates through business of developing and commercializing vaccines segment. The Firm has one product candidate in Phase II clinical development: GEN-003.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment